BRIM Biotechnology Inc. (BRIM) was established on July 31, 2013, in Taiwan by a group of seasoned international pharmaceutical experts. BRIM boasts a multidisciplinary team spanning science, engineering, and technology, focusing on efficient and cost-effective drug development processes. BRIM's senior team members have decades of experience in drug discovery, drug development, regulatory strategies, market analysis, and intellectual property protection, covering all critical stages of the drug development value chain, including preclinical studies, clinical sciences, and clinical trial management. With expertise in translational science and project integration, BRIM is committed to developing innovative therapies to combat and cure diseases for medically unmet patients.
Maximizing Value Through Strategic Selection and Resource Integration
At its core, BRIM leverages translational science and highly flexible project teams to integrate upstream and downstream resources in the healthcare industries. BRIM evaluates potential products from multiple perspectives, including scientific foundation, safety, developability, unmet medical needs, market competitiveness, clinical feasibility, and patent protection.
Using a project management approach, BRIM establishes robust patent strategies and collaborates with leading contract research organizations (CROs), contract manufacturing organizations (CMOs), and key opinion leaders (KOLs). This ensures innovative drugs progress efficiently to the "proof of concept" (POC) clinical stage. BRIM then partners with licensees and strategic collaborators to bring these products to market, achieving maximum value transformation from limited resources.
The PDSP Technology Platform: Multiple Advantages for Drug Development
In 2015, BRIM licensed the Pigment Epithelium-Derived Factor (PEDF)-Derived Short Peptides (PDSP) platform from Mackay Memorial Hospital. Preclinical studies confirmed its applications in repairing and treating various diseases, including corneal injury, osteoarthritis, wound healing, tendon injuries, and alopecia.
The PDSP platform uses solid-phase peptide synthesis (SPPS) for active pharmaceutical ingredient (API) production, offering high efficiency and yield while reducing manufacturing costs. PDSP's high safety and lack of immunogenicity, which shortens development timelines, and reduces R&D costs, providing multiple advantages for drug development.
Candidate Pipelines Addressing Urgent Medical Needs
As populations age and digital device usage increases, the prevalence of ophthalmic diseases, such as dry eye disease, glaucoma, and macular degeneration, has surged globally.
To address this growing demand, BRIM is developing multiple drug candidates to provide patients with innovative solutions. These include BRM421, a novel dry eye disease drug, and BRM424, a treatment for neurotrophic keratitis. Both drugs promote the proliferation and differentiation of limbal stem cells, accelerating corneal repair.
In 2024, BRIM expanded its ophthalmic portfolio by introducing two new drug products developed by the Industrial Technology Research Institute: BRM411, a dual-target inhibitor eye drop for glaucoma, and BRM412, an eye drop formulation for neovascular glaucoma. BRM411 effectively lowers intraocular pressure with low red-eye side effects, while BRM412 provides a convenient and low-side-effect alternative to traditional injectable drugs.
Beyond ophthalmology, BRIM is developing BRM521, an innovative treatment for osteoarthritis. This condition, the most common joint disease in developed countries, could be addressed by BRM521 through cartilage regeneration via chondrocyte proliferation and stem cell differentiation, reducing pain and inflammation.
Future Outlook
BRIM will continue focusing on developing therapies for unmet medical needs while actively expanding global collaborations. With its expertise and extensive experience, BRIM is committed to creating impactful innovations that combat and cure diseases, delivering value to both patients and investors.